The Role of Serum Soluble Urokinase-Type Plasminogen Activator Receptor in Stable Chronic Obstructive Pulmonary Disease

Basit Öğe Kaydı
dc.contributor.authorCan, Ummugulsum
dc.contributor.authorGuzelant, Asuman
dc.contributor.authorYerlikaya, Fatma Humeyra
dc.contributor.authorYosunkaya, Sebnem
dc.date.accessioned2024-02-23T14:21:12Z
dc.date.available2024-02-23T14:21:12Z
dc.date.issued2014
dc.departmentNEÜen_US
dc.description.abstractBackground: Chronic obstructive pulmonary disease (COPD) results from an abnormal inflammatory response of the lungs to noxious particles or gases. Serum soluble urokinase-type plasminogen activator receptor (suPAR) is a glycoprotein secreted during infections and inflammation. The main goal of this study was to evaluate the serum suPAR level in stable COPD patients compared with a control group. Methods: Forty-six stable COPD patients and 41 control subjects were included in the study. Blood samples were collected from 46 stable COPD patients (40 men, 6 women; mean [SD] age, 55.92 [7.91] years; the forced expiratory volume in 1 second, 45.32% [19.1%] of predicted). Forty-one healthy subjects were selected as control subjects and were matched to COPD patients with respect to age and body mass index. Serum suPAR and plasma fibrinogen levels were measured in stable COPD patients and control subjects. Results: Serum suPAR levels of the COPD patients were significantly higher than those of the control subjects (4.94 [2.79] and 2.40 [2.01] ng/mL, respectively; P < 0.001). Plasma fibrinogen levels of the COPD patients were significantly higher than those of the control subjects (406.77 [172.6] and 336.53 [96.1] g/L, respectively; P < 0.05). Conclusions: Our study indicated that serum suPAR may play an important role in the inflammatory process of COPD, and this increase may be particularly large for patients in Global Initiative for Chronic Obstructive Lung Disease stages III and IV. Serum suPAR and plasma fibrinogen level measurements may be useful for the evaluation of stable COPD.en_US
dc.identifier.doi10.1097/JIM.0000000000000105
dc.identifier.endpage943en_US
dc.identifier.issn1081-5589
dc.identifier.issn1708-8267
dc.identifier.issue7en_US
dc.identifier.pmid25127435en_US
dc.identifier.scopus2-s2.0-84927170372en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage938en_US
dc.identifier.urihttps://doi.org/10.1097/JIM.0000000000000105
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13487
dc.identifier.volume62en_US
dc.identifier.wosWOS:000343324000021en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBmj Publishing Groupen_US
dc.relation.ispartofJournal Of Investigative Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChronic Obstructive Pulmonary Diseaseen_US
dc.subjectSoluble Urokinase-Type Plasminogen Activator Receptoren_US
dc.subjectInflammationen_US
dc.titleThe Role of Serum Soluble Urokinase-Type Plasminogen Activator Receptor in Stable Chronic Obstructive Pulmonary Diseaseen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu